Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Asset Writedowns and Impairment (2016 - 2026)

Altimmune (ALT) reported Asset Writedowns and Impairment of $709000.0 for Q1 2026, down 78.52% on a QoQ basis from $3.3 million in Q4 2021.

Altimmune (ALT) has 5 years of Asset Writedowns and Impairment data on file, last reported at $709000.0 in Q1 2026.

  • Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $709000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.1 million (changed N/A YoY) and the FY2023 annual result came in at $12.4 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment declined to $709000.0 in Q1 2026 per ALT's latest filing, from $3.3 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $709000.0 in Q1 2026 and bottomed at $709000.0 in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Altimmune 379.61 Mn 379.61 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 709,000.00
Mar 31, 2026 709,000.00
Dec 31, 2021 3.30 Mn
Dec 31, 2021 3.30 Mn
Sep 30, 2021 30,000.00
Sep 30, 2021 30,000.00
Jun 30, 2021 8.07 Mn
Jun 30, 2021 8.07 Mn
Sep 30, 2019 1.00 Mn
Sep 30, 2019 1.00 Mn
Dec 31, 2018 24.45 Mn
Dec 31, 2018 24.45 Mn
Mar 31, 2018 490,676.00
Mar 31, 2018 490,676.00
Dec 31, 2016 2.56 Mn
Dec 31, 2016 2.56 Mn